Nathanson S D, Linden M D, Tender P, Zarbo R J, Jacobsen G, Nelson L T
Department of Surgery, Henry Ford Hospital, Detroit, Michigan 48202.
Dis Colon Rectum. 1994 Jun;37(6):527-34. doi: 10.1007/BF02050985.
We designed a study to determine whether increases in p53 protein in primary carcinomas of the colon or rectum correlate with overall survival. Mutations of the tumor suppressor gene p53 are detectable by immunocytochemical methods in colorectal cancers because of accumulation of nuclear p53 protein.
IgG1 monoclonal antibody to human p53 protein (PAb 1801) was used to detect p53 in formalin-fixed, paraffin-embedded archival tumors resected from 84 patients with tumor limited to the bowel wall. A multivariate analysis was performed using five prognostic pathobiologic variables compared with the level of staining of the p53 product.
Nuclear p53 protein was observed in 52 (62 percent) of 84 colorectal cancer patients with Stage T2 or T3, N0, M0 disease. Patients with strong expression (3+ and 4+) of p53 appeared to die from their disease sooner than those with weak expression (1+ and 2+), although this was not statistically significant (P > 0.59). Thirty-two patients did not express nuclear p53 by immunocytochemical methods. When these patients were analyzed in combination with the strong p53 expressors, the trend toward decreased survival increased (P > 0.15).
This data suggest that lack of p53 expression may also predict an adverse outcome in colorectal cancer. However, before the immunocytochemical method can be used clinically as a prognostic indicator, the colorectal cancer patients with zero expression should be studied further to clarify the functional status of p53 in their tumors.
我们设计了一项研究，以确定结肠或直肠癌原发癌中p53蛋白的增加是否与总生存期相关。由于核p53蛋白的积累，肿瘤抑制基因p53的突变可通过免疫细胞化学方法在结直肠癌中检测到。
使用针对人p53蛋白的IgG1单克隆抗体（PAb 1801）检测从84例肿瘤局限于肠壁的患者切除的福尔马林固定、石蜡包埋存档肿瘤中的p53。使用五个预后病理生物学变量与p53产物的染色水平进行多变量分析。
在84例T2或T3期、N0、M0疾病的结直肠癌患者中，52例（62%）观察到核p53蛋白。p53强表达（3+和4+）的患者似乎比弱表达（1+和2+）的患者死于疾病的时间更早，尽管这在统计学上不显著（P>0.59）。32例患者通过免疫细胞化学方法未表达核p53。当将这些患者与p53强表达者联合分析时，生存降低的趋势增加（P>0.15）。
这些数据表明，p53表达缺失也可能预示结直肠癌的不良预后。然而，在免疫细胞化学方法可作为临床预后指标使用之前，应进一步研究p53零表达的结直肠癌患者，以阐明其肿瘤中p53的功能状态。
